Growing investor interest sparks more funding for psychedelic clinical trials

The potential of psychedelics to treat a range of mental health conditions continues to attract increasing levels of funding for clinical trials as firms work towards bringing them into mainstream medical use.

Boston-based Preclinical neuroscience company Delix Therapeutics recently closed an initial Series A round of funding, in which it raised $70m for clinical trials of its psychoplastogen compounds.


Restricted content. Do you want to read more?